Table 1.
General characteristics, cardiovascular risk factors, and oncological history.
| Variable | Population n = 70 |
|---|---|
| Age, years | 60.3 ± 8.2 |
| Male sex, n (%) | 36 (51.4) |
| Weight, Kg | 73.3 ± 15.2 |
| Height, cm | 163 ± 11 |
| BSA, m2 | 1.78 ± 0.22 |
| BMI, Kg/m2 | 27.6 ± 4.7 |
| Cardiovascular risk factors | |
| Arterial hypertension, n (%) | 26 (37.1) |
| Obesity, n (%) | 22 (31.4) |
| Coronary artery disease, n (%) | 2 (2.9) |
| Diabetes, n (%) | 7 (10) |
| Chronic renal failure, n (%) | 6 (8.6) |
| Dyslipidemia, n (%) | 8 (11.4) |
| Active smoking/previous smoking, n (%) | 5 (7.1)/24 (34.3) |
| Oncological history | |
| MM duration, years | 4.3 ± 3.6 |
| Relapsed/Refractory MM, n (%) | 63 (90) |
| Previous therapy | |
| Antracyclines, n (%) | 26 (37.1) |
| Alkylating agents, n (%) | 59 (84.3) |
| Immunomodulating agents, n (%) | 42 (60) |
| Bortezomib, n (%) | 56 (80) |
| MM staging | |
| DS: stage I-I–III (%) | 9.1-27.3–63.6 |
| ISS: stage I-I–III (%) | 53.5-30.2–16.3 |
| Total carfilzomib dose, mg/m2 | 665 [295; 1 082] |
* Quantitative values are expressed as mean ± SD or median [interquantile range]. BSA = body surface area; BMI = body mass index; MM = multiple myeloma; DS = Durie-Salmon classification; ISS = International Staging System.